MedTrace Logo

Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

NCT02104323 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-02-09

No results posted yet for this study

Summary

1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an objective basis for an enlarged randomized double-blind trial.

Conditions

  • Vestibular Schwannoma
  • Neurofibromatosis Type 2

Interventions

DRUG

Endostatin

Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.

Sponsors & Collaborators

  • Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd

    collaborator INDUSTRY

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Pinan Liu · Beijing Tiantan Hospital

  • Fu Zhao · Beijing Neurosurgical Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02104323 on ClinicalTrials.gov